About the Program
Program Overview
As HIV-positive individuals live longer due to the use of highly active antiretroviral therapy (HAART), coronary heart disease (CHD) has become an increasingly important and pressing concern. This program will review and explain risk assessment, management and potential avoidance of CHD in HIV-positive patients. A cardiologist and an HIV expert will discuss and explore the risks associated with CHD in these patients and effective strategies and treatments for reducing or avoiding those risks. The most recent data regarding CHD in HIV-positive patients will be presented, including those presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), along with highly interactive case studies.
This tuition-free program is for health care providers who treat HIV-positive patients and there are no prerequisites.
Presented By:
Supported by an educational grant from Gilead Sciences
Back to Top
Learning Objectives and Program Details
After participating in this activity, the participants should be able to:
-
Clinically assess and utilize risk factors for coronary heart disease (CHD) and predict an HIV-positive patient’s pre-ARV treatment risk of CHD
-
Describe, discuss and apply the data from the SMART study on CHD risk associated with ARV treatment interruption and be able to integrate these data into ARV treatment plans and algorithms for HIV-positive patients
-
Analyze and apply current data on the risk of CHD associated with certain ARV drugs and/or regimens and use this information to select ARV drugs and regimens that minimize CHD risk for HIV-positive patients, and, in particular, for those patients with increased baseline risk for CHD
-
Analyze and use in clinical cases the current clinical trial data on treatment of hyperlipidemia, hyperglycemia and other CHD risk factors and use this information to select appropriate therapeutic strategies for HIV-positive patients to mitigate the CHD risk associated with them
Release Date: June 10, 2009
Expiration Date: June 10, 2010
Estimated time to complete this activity: 2 hours
Back to Top
Intended Audience
This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.
Back to Top
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of the CME activity
Course Directors
John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
Wendy Post, MD,
Associate Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
Faculty
Calvin Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts
Ian Frank, MD
Associate Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
Policy on Faculty and Provider Disclosures
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.
Dr. John Bartlett:
- Sources of Funding for Research: Gilead
- Consulting Agreements: Bristol-Myers Squibb; Tibotec; Abbott; GlaxoSmithKline
- Speakers' Bureau/Honorarium Agreements: None
- Financial Interests/Stock Ownership: None
- Other: None
Dr. Wendy Post:
- Sources of Funding for Research: None.
- Consulting Agreements: None.
- Speakers' Bureau/Honorarium Agreements: None.
- Financial Interests/Stock Ownership: None.
- Other: None.
Dr. Calvin Cohen:
- Sources of Funding for Research: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck & Co.; Pfizer; Tibotec.
- Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck & Co.; Pfizer; Tibotec; Virco.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead; Merck & Co.; Pfizer; Tibotec.
- Honorarium Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck & Co.; Pfizer; Tibotec.
- Financial Interests/Stock Ownership: None.
- Other: None.
Dr. Ian Frank:
- Sources of Funding for Research: Bavarian Nordic; Merck & Co.
- Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Pfizer.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Pfizer; Tibotec. Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Pfizer; Tibotec.
- Financial Interests/Stock Ownership: None.
- Other: None.
*This presentation includes information on studies and data presented at the 16th CROI involving off-label uses of efavirenz, nevirapine, raltegravir, abacavir, emtricitabine and atazanavir.
Back to Top
Instructions for Obtaining Continuing Medical Education Credit
In order to receive credit, participants must view the entire activity and complete a post test and activity evaluation online. Upon a successful score of 70% on the post test and completion of the evaluation, participants may print out their certificate. Participants may access the post test and evaluation for each activity by the links below.
Back to Top
Opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Copyright © 2009 The Johns Hopkins University School of Medicine. All rights reserved.
|
